Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543346 · ClinicalTrials.gov registry record · Phase 4
Comparability and Standardization of Controlled Allergen Challenge Facilities
A Phase 4 study of Allergic Rhinitis, sponsored by Queen's University.
- Completed
- Registry status
- Phase 4
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT02543346: Completed Phase 4 study of Allergic Rhinitis, sponsored by Queen's University.
NCT02543346 is a Phase 4 study of Allergic Rhinitis that has completed, run by Queen's University. The registered enrollment target is 98 participants, roughly in line with the 101-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02543346, a Phase 4 study of Allergic Rhinitis, has completed, sponsored by Queen's University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
Allergen challenge facilities have been utilized for many years in clinical drug trials studying onset of action, proof of concept, duration of action, and efficacy. Each facility has somewhat different design characteristics and pollen dispersal technologies. Facilities are located in disparate geographic areas and have populations of participants who are sensitized to allergens unique to that area. Therefore, facilities have operated as single sites with little effort to evaluate facility comparability or to attempt standardization across facilities. The purpose of this study is to compare the two sites and assess whether the sites are able to achieve similar symptom scores.
Primary Outcome
Participants recorded their nasal and ocular symptoms at baseline and during the intervention visits. The TRSS is a composite score comprised of 4 nasal (runny nose, sneezing, nasal itch, nasal congestion) and 3 ocular (itchy eyes, watery eyes, red/burning eyes) symptoms. The severity of each individual symptom is rated on a 4-point scale (0 to 3) and are summed for a maximum TRSS of 21 (0 to 21).The 4-point scale includes a severity score of 0 (None: no sign/symptom is evident), 1 (Mild: Sign/
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Cetirizine
Study Locations (2)
Texas
- Biogenics Research Chamber - San Antonio
Ontario
- Kingston General Hospital - Kingston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
What the finished NCT02543346 record still lists
NCT02543346 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, roughly in line with the 101-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02543346 reports a single indexed study location in Texas, Ontario.
Frequently Asked Questions
What is clinical trial NCT02543346 about?
NCT02543346 is a clinical study titled "Comparability and Standardization of Controlled Allergen Challenge Facilities". Allergen challenge facilities have been utilized for many years in clinical drug trials studying onset of action, proof of concept, duration of action, and efficacy. Each facility has somewhat different design characteristics and pollen dispersal technologies. Facilities are located in disparate geo...
What is the current status of trial NCT02543346?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 98 participants. The study started on 2015-10. Estimated completion is 2016-05.
What conditions does trial NCT02543346 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT02543346?
The interventions under investigation include: Placebo (OTHER), Cetirizine (DRUG).
Who is sponsoring clinical trial NCT02543346?
This trial is sponsored by Queen's University, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02543346 being conducted?
This trial has 2 study locations across Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02543346's enrollment target sits among peer trials
98 7th of 23 higher than 17 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
-
The Effect of Cetirizine on Bronchoconstriction
COMPLETED · Phase 4
-
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
COMPLETED · Phase 4
-
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
COMPLETED · Phase 4
-
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia